Quoin Pharmaceuticals LT-ADRQNRX
13F holders, Q2 2025 (June 30)6holders +5
6new positions
0sold out
$9.22avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Quoin Pharmaceuticals LT-ADR (QNRX) in their 13F filings, up 5 from Q1 2025. 6 opened new positions and 0 sold out. The largest holders were Rhumbline Advisers ($11K), Raymond James Financial Inc. ($7K) and GAMMA Investing LLC ($2K).
- Company
- Quoin Pharmaceuticals LT-ADR
- CUSIP
- 74907L409
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $23K |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 2,535 shares bought and 106 shares sold, net +2,429 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Rhumbline Advisers | 0.00% | New | 1,242 | $11K |
| Raymond James Financial Inc. | 0.00% | New | 717 | $7K |
| GAMMA Investing LLC | 0.00% | New | 240 | $2K |
| Morgan Stanley | 0.00% | New | 206 | $2K |
| UBS Group AG | 0.00% | New | 130 | $1K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -98.2% | 2 | $18 |
"% of holder's portfolio" is QNRX's weight in each manager's 13F, not the share of Quoin Pharmaceuticals LT-ADR the manager owns.